The role of histone lysine methyltransferase NSD3 in cancer

22Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

The growing number of findings demonstrate that nuclear receptor suppressor of variegation, enhancer of zeste, and trithorax domain-containing 3 (NSD3) is amplified and overexpressed in multiple cancer types. Nevertheless, the biological roles of NSD3 in carcinogenesis have not been well understood. In this review, we summarize the current knowledge on the mechanisms underlying NSD3 regulation in different cancers. In addition, NSD3 may serve as a potential druggable target for selective cancer therapy in the future.

Author supplied keywords

Cite

CITATION STYLE

APA

Han, X., Piao, L., Zhuang, Q., Yuan, X., Liu, Z., & He, X. (2018, July 5). The role of histone lysine methyltransferase NSD3 in cancer. OncoTargets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S166006

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free